<DOC>
	<DOCNO>NCT00687323</DOCNO>
	<brief_summary>The primary objective study evaluate safety , tolerability , efficacy temozolomide acute myeloid leukemia ( AML ) myelodysplastic syndrome ( MDS ) participant candidate standard induction therapy exhibit low MGMT expression .</brief_summary>
	<brief_title>Study Temozolomide Previously Untreated Acute Myeloid Leukemia ( AML ) Myelodysplastic Syndrome ( MDS ) Participants With Low O6-Methylguanine Methyltransferase ( MGMT ) Expression ( P05052 )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Confirmed diagnosis acute myeloid leukemia ( AML ) , subtype except acute promyelocytic leukemia ( APL ) , World Health Organization ( WHO ) criterion , high risk MDS blast 10 20 % bone marrow . No prior AML chemotherapy except hydroxyurea . Leukemic blast count &lt; 30x10^9/L start therapy . Prior cytoreduction hydroxyurea ( maximum 14 day ) permit . Participant candidate aggressive induction base least one following : adverserisk cytogenetics ( complete partial deletion 5 7 , complex [ &gt; 3 ] cytogenetic abnormality , inv3 , 11q23 abnormality ) ; secondary AML ( antecedent hematologic disorder therapyrelated AML ) ; comorbid medical illness preclude standard induction therapy ; participant 's refusal standard induction therapy . Confirmed low MGMT expression ( MGMT : betaactin ≤0.2 ) , evaluate Western blot , weak MGMT expression define &gt; 0.2 ≤2.5 promoter methylated , upon Sponsor approval . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 . Use medically approve contraception fertile male female . Negative urine serum pregnancy test woman childbearing potential ( 72 hour prior Baseline ) . Serum bilirubin &gt; 2 time upper limit normal ( ULN ) , serum aspartate aminotransferase/ alanine aminotransferase &gt; 5 time ULN . Serum creatinine &gt; 200 umol/L . History malignancy within 1 year prior study entry , exception localize nonmelanomatous skin cancer cervical cancer situ . Presence active uncontrolled infection . Known human immunodeficiency virus ( HIV ) infection . Any medical condition may interfere protocol evaluation oral medication intake . Prior chemotherapy hydroxyurea .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>